Home›Revefenacin

Revefenacin

Also known as: Yupelri

AnticholinergicCholinergic Antagonists

Route: Respiratory (Inhalation)

3 interactions on record

Revefenacin has 3 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyclosporine, Rifampin, Anticholinergic-Containing Drugs. Patients taking Revefenacin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 2
Moderate: 1

Major (2)

Revefenacin + Cyclosporine— OATP1B1 and OATP1B3 inhibitor that may increase systemic exposure of revefenacin's active metabolite. Coadministration n…
Revefenacin + Rifampin— OATP1B1 and OATP1B3 inhibitor that may increase systemic exposure of revefenacin's active metabolite. Coadministration n…

Moderate (1)

Revefenacin + Anticholinergic-Containing Drugs— May interact additively with revefenacin, leading to increased anticholinergic adverse effects. Avoid coadministration.

Revefenacin + Cyclosporine⚠️Major

OATP1B1 and OATP1B3 inhibitor that may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended.

Revefenacin + Rifampin⚠️Major

OATP1B1 and OATP1B3 inhibitor that may increase systemic exposure of revefenacin's active metabolite. Coadministration not recommended.

Revefenacin + Anticholinergic-Containing Drugs🟡Moderate

May interact additively with revefenacin, leading to increased anticholinergic adverse effects. Avoid coadministration.

Contraindications

4 CONTRAINDICATIONS YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product. YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with YUPELRI in pregnant women. Women should be advised to contact their physician if they become pregnant while taking YUPELRI. In animal reproduction studies, subcutaneous administration of revefenacin to pregnant rats and rabbits during the period of organogenesis produced no evidence of fetal harm at respective exposures approximately 209 times the exposure at the maximum recommended human dose (MRHD) (on an area under the curve [AUC] basis) (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In an embryo‑fetal development study in pregnant rats dosed during the period of organogenesis from gestation days 6 to 17, revefenacin was not teratogenic and did not affect fetal survival at exposures up to 209 times the MRHD (based upon summed AUCs for revefenacin and its active metabolite at maternal subcutaneous doses up to 500 mcg/kg/day). In an embryo‑fetal development study in pregnant rabbits dosed during the period of organogenesis from gestation days 7 to 19, revefenacin was not teratogenic and did not affect fetal survival at exposures up to 694 times the MRHD (based upon summed AUCs for revefenacin and its active metabolite at maternal subcutaneous doses up to 500 mcg/kg/day). Placental transfer of revefenacin and its active metabolite was observed in pregnant rabbits. In a pre- and postnatal development (PPND) study in pregnant rats dosed during the periods of organogenesis and lactation from gestation day 6 to lactation day 20, revefenacin had no adverse developmental effects on pups at exposures up to 196 times the MRHD (based upon summed AUCs for revefenacin and its active metabolite at maternal subcutaneous doses up to 500 m

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.